Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 44535 results
Impax buys two generic products from Actavis
Impax Laboratories, Inc. announced that it has acquired from Actavis plc two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed.
Drug Research > Drug Delivery > News
Roche’s lung cancer drug alectinib gets approval in Japan
By PBR Staff Writer
Roche has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for alectinib to treat people living with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+).
Regulatory Affairs > News
Bayer's Nexavar gets Health Canada approval for differentiated thyroid cancer
Bayer is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Drug Research > Drug Discovery & Development > News
Celladon announces new clinical development initiatives for MYDICAR
Celladon Corporation has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies.
Drug Research > Drug Discovery & Development > News
European Commission grants marketing approval for GSK and Genmab's Arzerra
By PBR Staff Writer
The European Commission has granted marketing authorisation for GlaxoSmithKline (GSK) and Genmab's Arzerra as first-line treatment for chronic lymphocytic leukaemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy.
Regulatory Affairs > News
Santen closes asset purchase agreement with Merck for ophthalmology assets
By PBR Staff Writer
Japan-based Santen Pharmaceutical has closed an asset purchase agreement which was entered on 13 May 2014 with Merck regarding the acquisition of certain ophthalmology assets, following the fulfillment of all of the transfer conditions, except in some territories, in accordance with the terms of the agreement.
Production & Manufacturing > Manufacturing > News
UCB, Dermira to develop and commercialize Cimzia in dermatology
By PBR Staff Writer
Belgium-based biopharmaceutical firm UCB has entered into an exclusive licensing agreement with Dermira, a US-based dermatology firm, to develop and future commercialize Cimzia (certolizumab pegol) in dermatology.
Contract Research & Services > Contract Services > News
Detained investigator says mass bribery at GSK China 'credible'
By PBR Staff Writer
Accusations that British drug-maker GlaxoSmithKline (GSK) has consistently bribed Chinese doctors to boost the sales of its drugs is ‘credible’, according to Peter Humphrey, who was hired to investigate the issue.
Production & Manufacturing > Manufacturing > News
Teva files citizen petition for approval of generic COPAXONE
Teva Pharmaceutical Industries Ltd., (TEVA) announced that the Company has filed a citizen petition (CP) regarding the approvability of purported generic versions of COPAXONE.
Drug Research > Drug Delivery > News
Natural Alternatives announces dismissal of all product liability suits involving CarnoSyn Beta-Alanine
Natural Alternatives International, Inc. (NAI) (NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the plaintiffs in four product liability suits have dismissed all of their claims against NAI relating to CarnoSyn® beta-alanine.
News
Advanced Cell Technology announces $30 million equity facility with Lincoln Park Capital
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”).
News
Medicure purchases minority interest in Apicore
Medicure Inc., a specialty pharmaceutical company, today announced that the Company and its newly formed and wholly owned subsidiary, Medicure U.S.A. Inc. ("Medicure USA") have entered into an arrangement whereby they have acquired a minority interest in a pharmaceutical manufacturing business. Specifically, Medicure and Medicure USA have acquired a 6.09% equity interest (5.33% on a fully-diluted basis) (the "Ownership Interest") in two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore") will be wholly owned operating subsidiaries.
Production & Manufacturing > Manufacturing > News
BioAlliance's lymphoma drug Beleodaq gets accelerated approval from FDA
By PBR Staff Writer
France-based BioAlliance Pharma has received topotarget accelerated approval from the US Food and Drug Administration (FDA) for Beleodaq to treat patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).
Regulatory Affairs > News
Tweed collaborates with leading academics for research
Tweed Marijuana Inc. (TWD.V) is pleased to announce that its wholly owned subsidiary Tweed Inc. ("Tweed") is launching collaborative research with researchers from two leading Canadian universities at its facility in Smiths Falls, Ontario .
Contract Research & Services > Contract Research > News
Genentech agrees to buy Seragon Pharmaceuticals
By PBR Staff Writer
Genentech, a member of the Roche Group, has entered into a definitive agreement to acquire the US-based biotechnology company Seragon Pharmaceuticals.
Production & Manufacturing > Manufacturing > News
136-150 of 44535 results